We actually discovered over-the-counter selling of antibiotics
@cmicomms.bsky.social

Now on stage #ESCMIDGlobal2025 dr Cristina Prat presenting data from the ongoing PNEUMO study that aims to quantify the seroprevalence of pneumococcal pneumonia and invasive disease. @ecraid.bsky.social @umcutrecht.bsky.social

Nice to see the results from the @ecraid.bsky.social POS-cUTI presented by Chantal Kats, treatment duration of complicated UTI is very heterogeneous and some baseline characteristics are prognostic for durations of >14 days. Results from 1st 1000 patients, currently >3000 in the study.

Excellent presentation by Vitoria Colizza on the role of school closures during the pandemic at @escmid.bsky.social Global2025. For the Netherlands: 5 yrs after the fact I am less convinced that closing schools during the first wave was a stupid thing to do.

I’m in Austria

Today & tomorrow we're meeting in Cascais for the @ecraid.bsky.social Foundation Science Meeting and the General Assembly meetings of the @ec.europa.eu funded projects ECRAID-BASE and ECRAID-PRIME. If the wind is fierce and cold, scientific collaboration must be strengthened. @escmid.bsky.social

On the origin of the MMR autism myth. Published in 2020, on page 354: "If 10.000 people say the same thing (autism bc of MMR) - the 10.000 mothers - anecdotes ultimately become science," was how the lawyer Robert Kennedy presented the argument at an anti-vaccine rally in Atlanta.
👇

Preparing my talk for the AMR Conference next week in Basel. Clinical endpoints for hospital/ventilator-associated pneumonia: all-cause mortality or clinical cure? Or something else, including both? Ecraid study: 30 ICU's, countries, almost 5K patients at risk for VAP, 17% developing VAP.

Vandaag een andere start dan gebruikelijk (onderzoeksoverleg). Behandeling zaak waarin @umcutrecht.bsky.social verantwoordelijk gesteld wordt voor oplopen COVID-19 infectie van medewerker (die vervolgens Long-COVID kreeg).

Zit klaar. Nu op NPO1 Spraakmakers, omdat ongeveer precies 5 jaar geleden de eerste mens COVID-19 moet hebben gehad @umcutrecht.bsky.social

Opmerkelijk bericht....

2-day meeting to align our actions for a coordinated research approach in Europe in case of a new infectious disease threat. View from the meeting room 👇
Where is the meeting?
@ec.europa.eu

2nd day of our annual meeting of PriMAVeRa; an IHI project in which the potential effects of vaccines and monoclonal antibodies on antimicrobial resistance is investigated using literature studies and mathematical modeling. See www.primavera/amr.eu

🙏🏾 to all lecturers & participants who joined the Ecraid x ESCMID 'Better Methods' postgrad course in Belgrade! The past three days of knowledge exchange were intense but so rewarding.
👉🏼 Discover more training opportunities and existing resources at ecraid.eu/education
media.licdn.com/dms/image/v2...

Better methods for clinical studies in infectious diseases & clinical microbiology!

3-day post-graduate course from ESCMID and Ecraid started this morning in Belgrade with course attendants, mostly young investigators, from multiple countries.

On stage Aleksandra Barac

Not just another day at the office.